ENOB Stock Overview
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$12.55|
|52 Week High||US$12.99|
|52 Week Low||US$2.80|
|1 Month Change||34.66%|
|3 Month Change||67.33%|
|1 Year Change||337.28%|
|3 Year Change||80.58%|
|5 Year Change||n/a|
|Change since IPO||83.21%|
Recent News & Updates
Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|ENOB||US Biotechs||US Market|
Return vs Industry: ENOB exceeded the US Biotechs industry which returned 4.1% over the past year.
Return vs Market: ENOB exceeded the US Market which returned 20% over the past year.
|ENOB Average Weekly Movement||8.8%|
|Biotechs Industry Average Movement||8.6%|
|Market Average Movement||6.0%|
|10% most volatile stocks in US Market||15.0%|
|10% least volatile stocks in US Market||2.3%|
Stable Share Price: ENOB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ENOB's weekly volatility (9%) has been stable over the past year.
About the Company
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.
Enochian Biosciences Fundamentals Summary
|ENOB fundamental statistics|
Is ENOB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ENOB income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.67|
|Net Profit Margin||0.00%|
How did ENOB perform over the long term?See historical performance and comparison
Is Enochian Biosciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ENOB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ENOB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ENOB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ENOB is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ENOB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ENOB is overvalued based on its PB Ratio (3.9x) compared to the US Biotechs industry average (2.8x).
How is Enochian Biosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Enochian Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Enochian Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ENOB is currently unprofitable.
Growing Profit Margin: ENOB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ENOB is unprofitable, and losses have increased over the past 5 years at a rate of 29.4% per year.
Accelerating Growth: Unable to compare ENOB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ENOB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: ENOB has a negative Return on Equity (-20.8%), as it is currently unprofitable.
How is Enochian Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: ENOB's short term assets ($15.5M) exceed its short term liabilities ($1.2M).
Long Term Liabilities: ENOB's short term assets ($15.5M) do not cover its long term liabilities ($15.9M).
Debt to Equity History and Analysis
Debt Level: ENOB has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ENOB's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ENOB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ENOB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 40.6% each year
What is Enochian Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ENOB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ENOB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ENOB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ENOB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ENOB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Dybul (58 yo)
Honorable Dr. Mark R. Dybul, M.D., serves as Chief Executive Officer at Enochian Biosciences, Inc. since July 1, 2021. He served as Executive Vice-Chair of Enochian Biosciences Inc. since January 7, 2019....
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD430.00K) is below average for companies of similar size in the US market ($USD2.29M).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
Experienced Management: ENOB's management team is considered experienced (2.8 years average tenure).
Experienced Board: ENOB's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12%.
Enochian Biosciences, Inc.'s employee growth, exchange listings and data sources
- Name: Enochian Biosciences, Inc.
- Ticker: ENOB
- Exchange: NasdaqCM
- Founded: 2017
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$655.357m
- Shares outstanding: 52.22m
- Website: https://www.enochianbio.com
Number of Employees
- Enochian Biosciences, Inc.
- Century City Medical Plaza
- Suite 906
- Los Angeles
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/01 00:13|
|End of Day Share Price||2021/11/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.